Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$7.00 CAD
Change Today +0.09 / 1.30%
Volume 14.2K
As of 3:02 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

biosyent inc (RX) Snapshot

Open
C$6.86
Previous Close
C$6.91
Day High
C$7.00
Day Low
C$6.86
52 Week High
09/19/14 - C$12.82
52 Week Low
08/24/15 - C$5.91
Market Cap
97.6M
Average Volume 10 Days
33.2K
EPS TTM
C$0.25
Shares Outstanding
13.9M
EX-Date
--
P/E TM
28.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOSYENT INC (RX)

Related News

No related news articles were found.

biosyent inc (RX) Related Businessweek News

No Related Businessweek News Found

biosyent inc (RX) Details

BioSyent Inc., a life science company, sources, acquires, in-licenses, and sells various pharmaceutical products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; Aguettant System for pre-filled syringes that are used in hospital and acute care settings; Proktis-M, a rectal suppository to help healing of the anus and rectum; and RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy. The company’s products also comprise Cathejell Jelly 2% indicated for surface anesthesia and lubrication for various procedures, including male and female cystoscopies, catheterizations, and other endourethral operations; endoscopies, proctoscopies, rectoscopies, and tracheal intubations, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis. In addition, it manufactures and markets Protect-It, a non-chemical, food-safe grain insecticide used as a preventative treatment against insect infestations in stored grains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 1947 and is headquartered in Toronto, Canada.

Founded in 1947

biosyent inc (RX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: C$225.7K
Chief Financial Officer
Total Annual Compensation: C$136.6K
Vice President of Biosyent Pharma Inc
Total Annual Compensation: C$130.4K
Compensation as of Fiscal Year 2014.

biosyent inc (RX) Key Developments

BioSyent Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

BioSyent Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of CAD 3,593,998 compared to CAD 3,072,395 for the same period a year ago. EBITDA was CAD 1,176,105 compared to CAD 1,211,096 a year ago. Net income before tax was CAD 1,174,422 compared to CAD 1,219,855 a year ago. Net income after tax was CAD 851,039 compared to CAD 888,805 a year ago. For the six months, the company reported revenue of CAD 6,900,098 compared to CAD 5,520,496 for the same period a year ago. EBITDA was CAD 2,490,429 compared to CAD 1,897,379 a year ago. Net income before tax was CAD 2,494,355 compared to CAD 1,907,527 a year ago. Net income after tax was CAD 1,813,751 compared to CAD 1,400,226 a year ago.

BioSyent Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

BioSyent Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total sales of CAD 3,306,100, were 35% higher compared to CAD 2,448,101 in the corresponding prior year period. EBITDA was CAD 1,314,324 was 92% higher than CAD 686,283 in the corresponding prior year period. Net Income after Tax was CAD 962,712 or CAD 0.25 per diluted share increased by 88% over CAD 511,421 or CAD 0.15 per diluted share in the corresponding prior year period. Net Income before Tax was CAD 1,319,933 compared to CAD 687,672 in the corresponding prior year period.

BioSyent Inc. Presents at Bloom Burton & Co. Inc. Healthcare Investor Conference, May-05-2015 09:30 AM

BioSyent Inc. Presents at Bloom Burton & Co. Inc. Healthcare Investor Conference, May-05-2015 09:30 AM. Venue: Sheraton Centre Toronto Hotel (Corner of York and Queen St. West), Toronto, Ontario, M5H 3M9, Canada. Speakers: René C. Goehrum, Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RX:CN C$7.00 CAD +0.09

RX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RX.
View Industry Companies
 

Industry Analysis

RX

Industry Average

Valuation RX Industry Range
Price/Earnings 26.2x
Price/Sales 6.6x
Price/Book 9.0x
Price/Cash Flow 25.4x
TEV/Sales 6.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOSYENT INC, please visit www.biosyent.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.